Table 2.
HRs for pneumonia and any infection requiring hospitalization, RA TennCare cohort (1995–2005)
| Number of episodes | Time, median (IQR), days* | Events | Crude HR (95% CI) | Age, gender- adjusted HR (95% CI) | PS-adjusted HRa (95% CI) | |
|---|---|---|---|---|---|---|
| Pneumonia | ||||||
| MTX | 4355 | 60 (41–133) | 32 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| TNF-α antagonists | 2192 | 68 (27–168) | 19 | 1.17 (0.67, 2.05) | 1.28 (0.73, 2.24) | 1.61 (0.85, 3.03) |
| LEF | 1097 | 43 (20–114) | 11 | 1.64 (0.79, 3.39) | 1.64 (0.79, 3.39) | 1.65 (0.77, 3.54) |
| SSZ | 1283 | 43 (28–51) | 3 | 0.47 (0.14, 1.53) | 0.51 (0.16, 1.68) | 0.60 (0.19, 1.97) |
| HCQ | 3398 | 43 (43–120) | 27 | 1.11 (0.67, 1.85) | 1.20 (0.72, 2) | 1.24 (0.73, 2.08) |
| Glucocorticoids (low dose)b | 2058 | 34 (23–43) | 17 | 2.00 (1.1, 3.64) | 1.71 (0.94, 3.1) | 2.30 (1.2, 4.41) |
| Glucocorticoids (medium dose) | 11 117 | 19 (19–23) | 53 | 2.08 (1.31, 3.3) | 1.92 (1.22, 3.01) | 2.36 (1.44, 3.87) |
| Glucocorticoids (high dose) | 3406 | 19 (18–25) | 30 | 3.91 (2.31, 6.62) | 3.67 (2.19, 6.15) | 4.33 (2.49, 7.54) |
| Any infection | ||||||
| MTX | 4355 | 60 (41–133) | 55 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| TNF-α antagonists | 2192 | 67 (27–167) | 29 | 1.04 (0.66, 1.64) | 1.12 (0.71, 1.77) | 1.31 (0.78, 2.19) |
| LEF | 1097 | 43 (20–114) | 16 | 1.39 (0.78, 2.48) | 1.39 (0.78, 2.48) | 1.48 (0.81, 2.69) |
| SSZ | 1283 | 43 (28–51) | 9 | 0.82 (0.4, 1.66) | 0.89 (0.44, 1.8) | 1.03 (0.51, 2.1) |
| HCQ | 3398 | 43 (43–119) | 44 | 1.06 (0.71, 1.56) | 1.13 (0.76, 1.67) | 1.20 (0.81, 1.79) |
| Glucocorticoids (low dose)b | 2058 | 34 (23–43) | 21 | 1.46 (0.88, 2.43) | 1.28 (0.77, 2.13) | 1.62 (0.94, 2.78) |
| Glucocorticoids (medium dose) | 11 117 | 19 (19–23) | 90 | 2.12 (1.47, 3.05) | 1.98 (1.38, 2.83) | 2.39 (1.63, 3.51) |
| Glucocorticoids (high dose) | 3406 | 19 (18–25) | 43 | 3.37 (2.19, 5.19) | 3.21 (2.1, 4.9) | 3.72 (2.37, 5.84) |
aPS-adjusted HRs accounted for all study covariates. bLow dose: <7.5 mg; medium dose: 7.5–30 mg; high dose: >30 mg of prednisone equivalents per day. PS: propensity score; IQR: interquartile range.